NCT02724852

MMR Vaccination Among HIV-infected Adults

Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 632 (actual)
• Sponsor: Chiang Mai University · Academic / Other
• Sex: All
• Age: 20 Years – 59 Years
• Healthy volunteers: Accepted

Summary

This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls. MMR vaccination were provided to both groups who had no protective antibodies to at least one of the three viruses.

Detailed description

From July to August 2011, 500 HIV-infected and 132 HIV-uninfected participants those met the eligibility criteria were enrolled and tested for protective antibodies to measles, mumps, and rubella. All participants who had no protective antibody to at least one of the three viruses were recruited to vaccinate for MMR vaccine. Between June to September 2012, 249 HIV-infected and 46 HIV-uninfected adults were vaccinated. Antibodies to MMR were measured at week 8-12, and week 48 after vaccination, which were completed in August 2013. The results were ready for analysis in March 2014.

Conditions

• HIV

Interventions

Type	Name	Description
BIOLOGICAL	0.5 ml of MMR vaccine	Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-09-01
• Completion: 2014-03-01
• First posted: 2016-03-31
• Last updated: 2016-04-01

Locations

1 site across 1 country: Thailand